Double-blind, placebo-controlled, hormonal, syndromal and EEG mapping studies with transdermal oestradiol therapy in menopausal depression
- PMID: 8657828
- DOI: 10.1007/BF02246261
Double-blind, placebo-controlled, hormonal, syndromal and EEG mapping studies with transdermal oestradiol therapy in menopausal depression
Abstract
In a double-blind, placebo-controlled study, the antidepressant and vigilance-promoting properties of transdermal oestrogen in post-menopausal depression were investigated utilizing hormonal, syndromal and EEG mapping evaluations. Sixty-nine menopausal women, aged 45-60 years without previous hormonal replacement therapy, diagnosed as major depression without psychotic or suicidal symptoms (DSM-III-R criteria), were randomly assigned to a 3-month treatment with transdermal oestradiol [Estraderm TTS (ETTS) 50 micrograms, applied twice weekly] or placebo. No other psychoactive medication was allowed. After removal of protocol violators, 32 patients were evaluable in each group, which did not differ in age, height or weight. As five patients discontinued prematurely in both groups and in one placebo patient a post-drug EEG could not be obtained, 27 patients remained in the ETTS and 26 in the placebo group for efficacy analysis. While in the placebo group, oestradiol (E2) and follicle stimulating hormone (FSH) remained unchanged, E2 increased and FSH decreased significantly in the ETTS group. Syndromal evaluation showed a significant improvement in the Kupperman Index (KI) as well as Hamilton Depression Rating Scale (HAMD) in both groups, with no inter-group difference. However, EEG mapping demonstrated significant inter-drug differences in brain function, mostly over the left temporal region. While ETTS patients showed an increase of alpha and alpha-adjacent theta activity and a decrease of beta activity, as well as an acceleration of the delta/theta centroid and a slowing of the alpha, beta and total power centroid, no changes occurred in the placebo-treated patients. These neurophysiological findings suggest improvement of vigilance by oestrogen, previously referred to as "mental tonic" effect. There were no changes, however, in the frontal alpha asymmetry index, reflecting left frontal hypo- and right frontal hyperactivation. Thus, this neurophysiological variable represents a state-independent marker for depression. The tolerability of ETTS was very good.
Similar articles
-
Hormonal, syndromal and EEG mapping studies in menopausal syndrome patients with and without depression as compared with controls.Maturitas. 1996 Feb;23(1):91-105. doi: 10.1016/0378-5122(95)00946-9. Maturitas. 1996. PMID: 8861091 Clinical Trial.
-
Hormone replacement therapy and vigilance: double-blind, placebo-controlled EEG-mapping studies with an estrogen-progestogen combination (Climodien, Lafamme) versus estrogen alone in menopausal syndrome patients.Maturitas. 2002 Nov 20;43(3):165-81. doi: 10.1016/s0378-5122(02)00201-3. Maturitas. 2002. PMID: 12443834 Clinical Trial.
-
EEG topography and tomography (LORETA) in diagnosis and pharmacotherapy of depression.Clin EEG Neurosci. 2010 Oct;41(4):203-10. doi: 10.1177/155005941004100407. Clin EEG Neurosci. 2010. PMID: 21077572 Clinical Trial.
-
Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial.Arch Gen Psychiatry. 2001 Jun;58(6):529-34. doi: 10.1001/archpsyc.58.6.529. Arch Gen Psychiatry. 2001. PMID: 11386980 Clinical Trial.
-
Use of transdermal oestradiol (Estraderm TTS) in hypertensive postmenopausal women.Br J Clin Pract Suppl. 1996 Sep;86:14-6. Br J Clin Pract Suppl. 1996. PMID: 8995005 Review. No abstract available.
Cited by
-
Identifying target regions for vigilance improvement under hormone replacement therapy in postmenopausal syndrome patients by means of electroencephalographic tomography (LORETA).Psychopharmacology (Berl). 2005 Apr;178(4):389-99. doi: 10.1007/s00213-004-2029-x. Epub 2004 Nov 3. Psychopharmacology (Berl). 2005. PMID: 15765254 Clinical Trial.
-
Sex differences in innate and adaptive neural oscillatory patterns link resilience and susceptibility to chronic stress in rats.J Psychiatry Neurosci. 2021 Mar 26;46(2):E258-E270. doi: 10.1503/jpn.200117. J Psychiatry Neurosci. 2021. PMID: 33769022 Free PMC article.
-
Reproductive hormonal treatments for mood disorders in women.Dialogues Clin Neurosci. 2002 Jun;4(2):211-23. doi: 10.31887/DCNS.2002.4.2/pschmidt. Dialogues Clin Neurosci. 2002. PMID: 22033644 Free PMC article.
-
The short-term effects of estradiol, raloxifene, and a phytoestrogen in women with perimenopausal depression.Menopause. 2021 Jan 15;28(4):369-383. doi: 10.1097/GME.0000000000001724. Menopause. 2021. PMID: 33470755 Free PMC article. Clinical Trial.
-
Role of estrogen in the aetiology and treatment of mood disorders.CNS Drugs. 2001;15(10):797-817. doi: 10.2165/00023210-200115100-00005. CNS Drugs. 2001. PMID: 11602005 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials